Patrick Yang - Eiger Biopharmaceutica Director
Director
Dr. Patrick Y. Yang, Ph.D., is Director of Celladon Corporationrationration. Patrick Y. Yang, Ph.D., 67, has served on our Board of Directors since March 2014. Dr. Yang recently retired from F. HoffmanLa Roche AG, a global pharmaceutical and diagnostics company, where he served as Executive Vice President and Global Head of Pharmaceutical Technical Operations from January 2010 until March 2013. In this role, Dr. Yang was responsible for Roches pharmaceutical and biotechnology manufacturing operations, process development, quality, regulatory, supply management, distribution, and procurement functions, based in Switzerland. From December 2003 through December 2009, Dr. Yang worked for Genentech, Inc., a leading biotechnology company, where his most recent position was Executive Vice President of Product Operations responsible for Genentechs manufacturing, engineering, process development, regulatory, quality, compliance, and supply chain management functions. Prior to Genentech, Dr. Yang held several leadership roles at Merck, including Vice President of AsiaPacific Operations and Vice President of Supply Chain Management. He also previously worked at General Electric Co. and Life Systems, Inc. in research, development, and manufacturing operations. Dr. Yang currently works as a biotech industry consultant. He serves on the board of directors of Tesoro Corporationrationration, a publicly held company in the business of refining and marketing petroleum products, the board of directors of Codexis, Inc., a publicly held company in the development and production of custom industrial enzymes for use in the pharmaceutical, chemical and biofuel production and on the board of directors of Amyris, Inc., a synthetic biology company since 2014.
| Age | 70 |
| Tenure | 10 years |
| Professional Marks | Ph.D |
| Address | 2155 Park Boulevard, Palo Alto, CA, United States, 94306 |
| Phone | 650 272 6138 |
| Web | https://www.eigerbio.com |
Patrick Yang Latest Insider Activity
Tracking and analyzing the buying and selling activities of Patrick Yang against Eiger Biopharmaceutica stock is an integral part of due diligence when investing in Eiger Biopharmaceutica. Patrick Yang insider activity provides valuable insight into whether Eiger Biopharmaceutica is net buyers or sellers over its current business cycle. Note, Eiger Biopharmaceutica insiders must abide by specific rules, including filing SEC forms every time they buy or sell Eiger Biopharmaceutica'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Patrick Yang over a year ago Purchase by Patrick Yang of 6000 shares of Codexis |
Eiger Biopharmaceutica Management Efficiency
The company has return on total asset (ROA) of (0.5244) % which means that it has lost $0.5244 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.2593) %, meaning that it created substantial loss on money invested by shareholders. Eiger Biopharmaceutica's management efficiency ratios could be used to measure how well Eiger Biopharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Eiger Biopharmaceutica's Return On Capital Employed is relatively stable compared to the past year. As of 05/01/2024, Return On Equity is likely to grow to 5.44, though Return On Tangible Assets are likely to grow to (1.83). At this time, Eiger Biopharmaceutica's Other Assets are relatively stable compared to the past year. As of 05/01/2024, Debt To Assets is likely to grow to 1.11, while Non Current Assets Total are likely to drop slightly above 937.6 K.The company currently holds 41.2 M in liabilities with Debt to Equity (D/E) ratio of 0.38, which is about average as compared to similar companies. Eiger Biopharmaceuticals has a current ratio of 7.08, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Eiger Biopharmaceutica until it has trouble settling it off, either with new capital or with free cash flow. So, Eiger Biopharmaceutica's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Eiger Biopharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Eiger to invest in growth at high rates of return. When we think about Eiger Biopharmaceutica's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Robert Iger | Apple Inc | 66 | |
| Jonathan Rubinstein | Amazon Inc | 61 | |
| Jamie Gorelick | Amazon Inc | 67 | |
| Mason Morfit | Microsoft | 40 | |
| Helmut Panke | Microsoft | 71 | |
| Susan Wagner | Apple Inc | 52 | |
| Arne Sorenson | Microsoft | 59 | |
| Suhasini Chandramouli | Apple Inc | N/A | |
| William Gates | Microsoft | 62 | |
| John Brown | Amazon Inc | 75 | |
| Reid Hoffman | Microsoft | 50 | |
| James Bell | Apple Inc | 69 | |
| Wendell Weeks | Amazon Inc | 58 | |
| Diane Greene | Alphabet Inc Class C | 62 | |
| Albert Gore | Apple Inc | 69 | |
| Paul Otellini | Alphabet Inc Class C | 65 | |
| Tom Alberg | Amazon Inc | 77 | |
| Roger Ferguson | Alphabet Inc Class C | 66 | |
| Bob Iger | Apple Inc | 64 | |
| John Hennessy | Alphabet Inc Class C | 65 | |
| Charles Noski | Microsoft | 65 | |
Management Performance
| Return On Equity | -2.26 | ||||
| Return On Asset | -0.52 |
Eiger Biopharmaceuticals Leadership Team
Elected by the shareholders, the Eiger Biopharmaceutica's board of directors comprises two types of representatives: Eiger Biopharmaceutica inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eiger. The board's role is to monitor Eiger Biopharmaceutica's management team and ensure that shareholders' interests are well served. Eiger Biopharmaceutica's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eiger Biopharmaceutica's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sriram MBA, Chief Officer | ||
| Christopher Kurtz, Chief Officer | ||
| Rebecque Laba, Vice President - Corporate Operations | ||
| David Apelian, Director | ||
| Patrick Yang, Director | ||
| Erik Atkisson, Corp Counsel | ||
| James Welch, CFO | ||
| MBA MD, CEO Director | ||
| William CPA, CFO Officer | ||
| Colin MD, Sr Operations | ||
| Edgar Engleman, Director | ||
| Jeffrey Rudy, Vice President - Clinical Operations | ||
| MBA III, Chief Officer | ||
| Charles Bramlage, Director | ||
| Thomas Dietz, Director | ||
| Jeysen Yogaratnam, Vice President of Global Hepatitis Delta Virus (HDV) Clinical Development | ||
| Dr JD, Consultant | ||
| Eldon Mayer, Director | ||
| Mark Mannebach, Vice President of Global Regulatory Affairs | ||
| James JD, Chief Counsel | ||
| Stephana Patton, Chief Compliance Officer, General Counsel, Secretary | ||
| Nina Kjellson, Director | ||
| Amit Sachdev, Independent Director | ||
| Ingrid Choong, VP Devel | ||
| Colleen MD, Senior Diseases | ||
| James Shaffer, Chief Business Officer | ||
| Christine Murray, Independent Director | ||
| David Cory, President CEO, Director | ||
| Rich MBA, VP Affairs | ||
| Sriram Ryali, CFO | ||
| Ryan Takeya, Vice President - Manufacturing | ||
| MBBS MD, Senior Operations | ||
| Evan Loh, Director | ||
| Jeffrey Glenn, Director | ||
| MBA MBA, President, Founder |
Eiger Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Eiger Biopharmaceutica a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.26 | ||||
| Return On Asset | -0.52 | ||||
| Operating Margin | (5.28) % | ||||
| Current Valuation | 3.88 M | ||||
| Shares Outstanding | 1.48 M | ||||
| Shares Owned By Insiders | 11.79 % | ||||
| Shares Owned By Institutions | 43.86 % | ||||
| Number Of Shares Shorted | 29.81 K | ||||
| Price To Earning | (2.04) X | ||||
| Price To Book | 0.87 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Eiger Biopharmaceutica in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Eiger Biopharmaceutica's short interest history, or implied volatility extrapolated from Eiger Biopharmaceutica options trading.
Pair Trading with Eiger Biopharmaceutica
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eiger Biopharmaceutica position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eiger Biopharmaceutica will appreciate offsetting losses from the drop in the long position's value.Moving together with Eiger Stock
| 0.77 | EVOK | Evoke Pharma | PairCorr |
Moving against Eiger Stock
| 0.8 | JAGX | Jaguar Animal Health Financial Report 20th of May 2024 | PairCorr |
| 0.69 | ELYM | Eliem Therapeutics Trending | PairCorr |
The ability to find closely correlated positions to Eiger Biopharmaceutica could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eiger Biopharmaceutica when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eiger Biopharmaceutica - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eiger Biopharmaceuticals to buy it.
The correlation of Eiger Biopharmaceutica is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eiger Biopharmaceutica moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eiger Biopharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eiger Biopharmaceutica can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Eiger Biopharmaceuticals information on this page should be used as a complementary analysis to other Eiger Biopharmaceutica's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Complementary Tools for Eiger Stock analysis
When running Eiger Biopharmaceutica's price analysis, check to measure Eiger Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eiger Biopharmaceutica is operating at the current time. Most of Eiger Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of Eiger Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eiger Biopharmaceutica's price. Additionally, you may evaluate how the addition of Eiger Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
Is Eiger Biopharmaceutica's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eiger Biopharmaceutica. If investors know Eiger will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eiger Biopharmaceutica listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (58.50) | Revenue Per Share 9.951 | Quarterly Revenue Growth (0.20) | Return On Assets (0.52) | Return On Equity (2.26) |
The market value of Eiger Biopharmaceuticals is measured differently than its book value, which is the value of Eiger that is recorded on the company's balance sheet. Investors also form their own opinion of Eiger Biopharmaceutica's value that differs from its market value or its book value, called intrinsic value, which is Eiger Biopharmaceutica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eiger Biopharmaceutica's market value can be influenced by many factors that don't directly affect Eiger Biopharmaceutica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eiger Biopharmaceutica's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eiger Biopharmaceutica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eiger Biopharmaceutica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.